Microbicide Trials Network

CLARIFICATION MEMO #01 TO:

MTN-013/IPM 026

Phase 1 Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

DAIDS Document ID: 11772

Date of Clarification Memorandum: 12 July 2011

Site Instruction and Summary of Clarification

The procedures clarified in this Clarification Memorandum (CM) have been approved by the NIAID Medical Officer and are to be implemented immediately upon issuance. IRB approval of this CM is not required by the sponsor; however, investigators may submit the CM to the IRB overseeing the study at their site for information. This CM is official MTN-013/IPM 026 documentation and is effective immediately. A copy of this CM must be retained in the study site's Essential Documents file for MTN-013/IPM 026. No change in informed consent is necessitated by or included in this CM.

The primary goal of this CM is to clarify the behavioral assessment schedule and measures utilized. Additional changes included in this CM include, updates to the roster and to the storage requirements for the study product.

Implementation

Except for modifications to the Protocol Team Roster, text to be deleted is noted by ~~strikethrough~~ and text to be added is noted below in **bold.**

---

1. The following individual was removed from the Protocol Team Roster: Jim Maynard.

2. Section 6.4.2, *Storage and Dispensing*, first sentence, has been updated to reflect the current storage requirements for the study products:

   The vaginal rings should be stored at **a controlled room temperature, 68°F to 77°F (20°C to 25°C), allowable excursions are between** ~~15°C to 30°C (~~59°F to 86°F~~)~~ **(15°C to 30°C)**.

3. Updates have been made to tables in Section 7.4.2, *Follow-up Visits*, and Appendix I, to streamline the behavioral assessment schedule and clarify the measures utilized:

Table 5: Visit Days 1, 2, 3, 5, 7, 14, 21

Follow-up Visits: Days 1, 2, 3, 5, 7, 14, 21	
Component	Procedures
Behavioral	• Conduct **behavioral** ~~adherence~~ assessment**s (protocol adherence**, **product use adherence)** ☼

Table 6: Visit Day 28

Follow-up Visit: Day 28	
Component	Procedures
Behavioral	• Conduct behavioral assessments **(protocol adherence, product use adherence, acceptability)** • ~~Conduct adherence assessments~~

Table 8: Visit Days 31, 35, 42

Follow-up Visits: Days 31, 35, 42	
Component	Procedures
Behavioral	• **Conduct behavioral assessment (protocol adherence)** ǂ

Table 9: Visit Day 52, Final Clinic/Early Termination Visit

Final Clinic/ Early Termination Visit: Visit Day 52	
Component	Procedures
Behavioral	• Conduct behavioral assessment**s (protocol adherence) (acceptability▲)** • ~~Conduct adherence assessment▲~~

Appendix I: Schedule of Study Visits and Evaluations

	SCR	ENR Day 0	VISIT DAYS 1, 2, 3, 5, 7, 14, 21	VISIT DAY 28	VISIT DAYS 29, 30	VISIT DAYS 31, 35, 42	DAY 52 Final Clinic/ **Early** Term.	Interim
BEHAVIORAL								
~~Conduct adherence assessment**(s)**~~			☼	~~X~~		ǂ	~~▲~~	
Conduct behavioral assessment	X	X		~~X~~			~~X~~	
Conduct acceptability assessment				**X**			▲	
Conduct protocol adherence assessment(s)			☼	**X**		ǂ	**X**	
Conduct product use adherence assessment(s)			☼	**X**				

4. Section 7.9, *Laboratory Evaluations*, Vaginal and Cervical sub-bullets, the protocol has been updated to reflect that biopsies will be obtained from the cervix not the vagina.

- Vaginal
  - ~~Biopsy for PK assessment~~

- Cervical
  - Biopsy for **PK and** PD assessment

5. Section 10.6, *Randomization*, first paragraph, fourth sentence has been removed to eliminate the requirement to stratify the randomization by site to the end of study period PK/PD sampling times given the number of sampling time points, number of sites and sample size:

   ~~This randomization will be stratified by site to ensure balanced assignment of PK/PD end of study period sampling timing~~.

The above information will be incorporated into the next version of the protocol at a later time if it is amended.